191 related articles for article (PubMed ID: 29392480)
1. Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.
Gelhorn HL; Skalicky AM; Balantac Z; Eremenco S; Cimms T; Halling K; Hollen PJ; Gralla RJ; Mahoney MC; Sexton C
Support Care Cancer; 2018 Jul; 26(7):2229-2238. PubMed ID: 29392480
[TBL] [Abstract][Full Text] [Related]
2. Content validity and ePRO usability of the BPI-sf and "worst pain" item with pleural and peritoneal mesothelioma.
Gelhorn HL; Eremenco S; Skalicky AM; Balantac Z; Cimms T; Halling K; Sexton C
J Patient Rep Outcomes; 2017; 2(1):16. PubMed ID: 29749970
[TBL] [Abstract][Full Text] [Related]
3. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Cancer; 2004 Aug; 101(3):587-95. PubMed ID: 15274072
[TBL] [Abstract][Full Text] [Related]
4. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Support Care Cancer; 2006 Jan; 14(1):11-21. PubMed ID: 15999264
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Mixed-Methods Study of Malignant Pleural Mesothelioma Symptoms.
Walker SL; Vaughan Dickson V; Cacchione PZ
Oncol Nurs Forum; 2022 Oct; 49(6):615-623. PubMed ID: 36413739
[TBL] [Abstract][Full Text] [Related]
6. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Williams LA; Whisenant MS; Mendoza TR; Haq S; Keating KN; Cuffel B; Cleeland CS
Qual Life Res; 2018 Dec; 27(12):3229-3241. PubMed ID: 30187393
[TBL] [Abstract][Full Text] [Related]
7. A Qualitative Study to Assess the Content Validity of the 24-Hour Migraine Quality of Life Questionnaire in Patients with Migraine.
Speck RM; Collins EM; Lombard L; Ayer DW
Headache; 2020 Oct; 60(9):1982-1994. PubMed ID: 32748408
[TBL] [Abstract][Full Text] [Related]
8. Advanced Symptom Management System for Patients with Malignant Pleural Mesothelioma (ASyMSmeso): Mixed Methods Study.
Maguire R; Connaghan J; Arber A; Klepacz N; Blyth KG; McPhelim J; Murray P; Rupani H; Chauhan A; Williams P; McNaughton L; Woods K; Moylan A
J Med Internet Res; 2020 Nov; 22(11):e19180. PubMed ID: 33180025
[TBL] [Abstract][Full Text] [Related]
9. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH.
McCollister D; Shaffer S; Badesch DB; Filusch A; Hunsche E; Schüler R; Wiklund I; Peacock A;
Respir Res; 2016 Jun; 17(1):72. PubMed ID: 27301413
[TBL] [Abstract][Full Text] [Related]
10. Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire, and Hidradenitis Suppurativa Quality of Life Questionnaire.
Ingram JR; Ciaravino V; Rolleri R; Pansar I; Dias-Barbosa C; Kirby JS
Dermatology; 2024; 240(1):65-76. PubMed ID: 37820596
[TBL] [Abstract][Full Text] [Related]
11. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
Moore A; Bennett B; Taylor-Stokes G; McDonald L; Daumont MJ
BMC Cancer; 2022 Jun; 22(1):693. PubMed ID: 35739480
[TBL] [Abstract][Full Text] [Related]
12. A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life?
Hollen PJ; Gralla RJ; Kris MG; McCoy S; Donaldson GW; Moinpour CM
Qual Life Res; 2005 Apr; 14(3):837-47. PubMed ID: 16022076
[TBL] [Abstract][Full Text] [Related]
13. Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.
McCarrier KP; Atkinson TM; DeBusk KP; Liepa AM; Scanlon M; Coons SJ;
Clin Ther; 2016 Apr; 38(4):794-810. PubMed ID: 27041408
[TBL] [Abstract][Full Text] [Related]
14. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
[TBL] [Abstract][Full Text] [Related]
15. Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity.
Askanase AD; Daly RP; Okado M; Neville K; Pong A; Hanrahan LM; Merrill JT
Health Qual Life Outcomes; 2019 Jun; 17(1):99. PubMed ID: 31174541
[TBL] [Abstract][Full Text] [Related]
16. Symptom Burden and Unmet Needs in Malignant Pleural Mesothelioma: Exploratory Analyses From the RESPECT-Meso Study.
Hoon SN; Lawrie I; Qi C; Rahman N; Maskell N; Forbes K; Gerry S; Monterosso L; Chauhan A; Brims FJH
J Palliat Care; 2021 Apr; 36(2):113-120. PubMed ID: 32791881
[TBL] [Abstract][Full Text] [Related]
17. Development and usability testing of an electronic patient-reported outcome (ePRO) solution for patients with inflammatory diseases in an Advanced Therapy Medicinal Product (ATMP) basket trial.
McMullan C; Retzer A; Hughes SE; Aiyegbusi OL; Bathurst C; Boyd A; Coleman J; Davies EH; Denniston AK; Dunster H; Frost C; Harding R; Hunn A; Kyte D; Malpass R; McNamara G; Mitchell S; Mittal S; Newsome PN; Price G; Rowe A; van Reil W; Walker A; Wilson R; Calvert M
J Patient Rep Outcomes; 2023 Oct; 7(1):98. PubMed ID: 37812323
[TBL] [Abstract][Full Text] [Related]
18. Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
BMC Cancer; 2018 Mar; 18(1):350. PubMed ID: 29587685
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Mendoza TR; Williams LA; Keating KN; Siegel J; Elbi C; Nowak AK; Hassan R; Cuffel B; Cleeland CS
J Patient Rep Outcomes; 2019 Jun; 3(1):34. PubMed ID: 31209661
[TBL] [Abstract][Full Text] [Related]
20. Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.
Mathias SD; Vallow S; Gipson DS; Thorneloe KS; Sprecher D
Am J Kidney Dis; 2017 Oct; 70(4):532-540. PubMed ID: 28663063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
